Insulin-Like Growth Factor I for Multiple Sclerosis Treatments
[Federal Register: July 17, 1996 (Volume 61, Number 138, Page 37280]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Prospective Grant of Exclusive License: Method of Treating
Demyelinating Diseases With Insulin-Like Growth Factor I
AGENCY: National Institutes of Health, Public Health Service, DHHS.
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license in the United States to practice the invention
embodied in U.S. Patent Application Serial Number 60/003,055, filed on
August 31, 1995, entitled ``Method of Treating Demyelinating Diseases
With Insulin-Like Growth Factor I'', to Cephalon, Inc., having a place
of business in West Chester, Pennsylvania. The patent rights in this
invention have been assigned to the United States of America.
The patent application claims a method to treat diseases or
disorders associated with myelin injury, such as multiple sclerosis, by
administering an effective amount of insulin-like growth factor I.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 90 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The field of use would be the use of insulin-like growth factor I
to treat nervous system disorders associated with perivascular lesions,
such as those occurring in multiple sclerosis.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Leopold J. Luberecki, Jr., J.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD
20852-3804. Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-
0200. Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Only written comments and/or application for a
license which are received by the NIH Office of Technology Transfer on
or before October 15, 1996 will be considered.
Comments and objections submitted in response to this notice will
not be made available for public inspection, and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: July 8, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-18102 Filed 7-16-96; 8:45 am]
BILLING CODE 4140-01-M